Used in combination with tocilizumab against IL-6. Showed improved survival rates for ovarian cancer in vivo. Enhances cancer treatment in HNSCC, pancreatic cancer, and glioblastoma. This evidence concerns the gene IL6 and head and neck squamous cell carcinoma.